Achieve (ACHV) Q2 Net Loss Hits $12.7M

Achieve Life Sciences (NASDAQ:ACHV), a late-stage biopharmaceutical firm focused on therapies for nicotine dependence, released its second-quarter fiscal 2025 results on August 7, 2025. The headline news: Achieve successfully filed its anticipated NDA for cytisinicline, its lead investigational therapy for smoking cessation, and secured a new commercialization partnership. Achieve reported a GAAP net loss per share of $(0.37), closely in line with the consensus GAAP EPS estimate of $(0.37). As expected for a pre-commercial biotech firm, revenue was zero. The company had $55.4 million in cash, cash equivalents, and marketable securities, boosted by recent financing. Overall, Achieve advanced essential milestones.

Source: Analyst estimates for the quarter provided by FactSet.

Achieve Life Sciences is a biopharmaceutical company developing new treatments for nicotine dependence, with a focus on its investigational drug cytisinicline. Cytisinicline is a plant-derived compound designed to help people stop smoking or vaping by targeting nicotine receptors in the brain.

Continue reading

Source Fool.com